SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

PRX-119

PLX·Protalix BioTherapeutics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical / Discovery
Time to market
Not stated
Why 2/10
PRX-119 is an early-stage/preclinical pipeline program at Protalix. No clinical trials, no regulatory filings, and no hard dated catalyst are scheduled in the next ~12 months. The company's near-term value is driven by its approved products (Elelyso, Elfabrio) and the Phase 2 PRX-115 gout program, not PRX-119.
Actionable Insight NEUTRAL

PRX-119 is too early-stage to drive a binary event. Watch Protalix's Q4 2026 revenue to see if full-year guidance of $78M-$83M is achievable, and monitor PRX-115 Phase 2 RELEASE study top-line results expected in H2 2027 for the next pipeline catalyst.

Price Chart

Loading chart...

Executive Summary

PRX-119 is an early-stage, preclinical pipeline program at Protalix BioTherapeutics (NYSE American: PLX), an Israeli biopharmaceutical company focused on rare diseases. The company's ProCellEx platform produces recombinant therapeutic proteins. While PRX-119 is named in Protalix's pipeline alongside the more advanced PRX-115 (Phase 2 for uncontrolled gout), no clinical data, indication, or development timeline for PRX-119 have been publicly disclosed. Protalix generates revenue from two approved products: Elelyso (for Gaucher disease, partnered with Pfizer) and Elfabrio (for Fabry disease, partnered with Chiesi). The company reported Q3 2026 revenue of $21.9M and net income of $4.0M, with full-year 2026 revenue guidance of $78M-$83M. PRX-119 is not a near-term catalyst for the stock.

How It Works

PRX-119 is an investigational drug candidate developed using Protalix's proprietary ProCellEx plant cell-based protein expression platform. Its specific molecular target and therapeutic indication have not been publicly disclosed.

Trial Status

PRX-119 is listed in Protalix's pipeline as a preclinical or early-stage program. No clinical trials have been initiated, and no data have been publicly reported. The company's Q3 2026 earnings release and SEC filings mention PRX-119 as a pipeline program but provide no details on indication, mechanism, or development timeline.

Upcoming Catalysts

  • No clinical milestones or regulatory catalysts for PRX-119 are scheduled in the next ~12 months

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Protalix BioTherapeutics, Inc. 8-K PLX ·Originating report

Sources · 6

Hover a chip for the title
1 aol.com2 rttnews.com3 seekingalpha.com4 sec.gov5 seekingalpha.com6 aol.com